Glycosaminoglycans (GAGs) have diverse functions in the body and are involved in viral infection. The purpose of this study was to evaluate the possible roles of the E-disaccharide units GlcAβ1-3GalNAc(4,6-O-disulfate) of chondroitin sulfate (CS), a GAG involved in neuritogenesis and neuronal migration, in Japanese encephalitis virus (JEV) infection. Soluble CS-E (sCS-E) derived from squid cartilage inhibited JEV infection in African green monkey kidney-derived Vero cells and baby hamster kidney-derived BHK cells by interfering with viral attachment. In contrast, sCS-E enhanced viral infection in the mouse neuroblastoma cell line Neuro-2a, despite the fact that viral attachment to Neuro-2a cells was inhibited by sCS-E. This enhancement effect in Neuro-2a cells seemed to be related to increased viral RNA replication and was also observed in a rat infection model in which intracerebral coadministration of sCS-E with JEV in 17-day-old rats resulted in higher brain viral loads than in rats infected without sCS-E administration. These results show the paradoxical effects of sCS-E on JEV infection in different cell types and indicate that potential use of sCS-E as an antiviral agent against JEV infection should be approached with caution considering its effects in the neuron, the major target of JEV.
Introduction
Japanese encephalitis virus (JEV) is a member of the Flaviviridae family that is transmitted primarily by Culex tritaeniorhynchus mosquitoes. Although most JEV infections in humans are asymptomatic, clinical cases tend to manifest as severe, often fatal encephalitis.
Neurons are the major target of JEV in the brain [1] . Proteoglycans (PGs), which are composed of glycosaminoglycans (GAGs) and core proteins, are major components of the cell surface and the extracellular matrix. Chondroitin sulfate (CS)-PG constitutes the major population of GAGs in the central nervous system (CNS). CS-PG plays important roles in the developing and adult CNS with respect to the regulation of cell proliferation, differentiation, neuronal migration, neurite extension, neural plasticity, and axonal regeneration [2] .
Recently, many researchers have been interested in the relationships between GAGs and viral infection. Some viruses use cell-surface PGs as their receptors [3] [4] [5] [6] [7] , and virus clearance involves extracellular and cell surface PGs in the bloodstream [8] . However, the role of CS in flavivirus infection, especially within the CNS, remains uncertain.
The purpose of this study was to investigate the influence of soluble CS-E rich in GlcAβ1-3GalNAc(4,6-O-disulfate) unit, on JEV infection in a neural cell line and in animal brains.
Material and methods
Cells, viruses, and reagents. Neuro-2a (mouse neuroblastoma) cells were grown in high-glucose Dulbecco's Modified Eagle Medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% fetal calf serum (FCS). Baby hamster kidney (BHK-21) cells were grown in DMEM supplemented with 10% FCS. African green monkey kidney (Vero) cells were grown in Minimum Essential Medium (Nissui, Tokyo, Japan) supplemented with 5% FCS. The JEV Nakayama strain was kindly provided by Dr. Ikuo Takashima (Hokkaido University, Sapporo, Japan) and was cloned by 3 rounds of plaque purification. Soluble CS (sCS) -A, -B, -C, -D, and -E were purchased from Seikagaku Corp. (Tokyo, Japan). Heparin was purchased from Sigma (St. Louis, MO)
Immunofluorescence. Cells were fixed with methanol-acetone (1:1, v/v) for 30 min, washed with phosphate-buffered saline (PBS), and blocked with 2% bovine serum albumin (BSA)-PBS. Cells were incubated with rabbit anti-JEV serum in 1% BSA-PBS at room temperature for 30 min, followed by incubation with Alexa-594-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA). The cell nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole). Fluorescence was observed with an inverted fluorescence microscope (IX70, Olympus, Tokyo, Japan). The number of JEV antigen-positive cells was counted by using MetaMorph software (MDS Analytical Technologies, Toronto, Canada).
Focus reduction assay.
A focus reduction assay was performed as described by Aoki et [9] with modifications. Briefly, 40 focus-forming units (FFU) of JEV were premixed with 10-fold serial dilutions of sCS-E and incubated at 4 °C for 30 min. The virus-sCS-E mixtures were then inoculated into BHK cells seeded in 96-well plates. After 2 h of incubation at 37 °C, overlay medium (DMEM containing 1% FBS and 0.5% methyl cellulose) was added to each well. The overlay medium was removed after 24 h of incubation at 37 °C, and the cells were washed with PBS. The cells were fixed with methanol-acetone (1:1, v/v) for 30 min, washed with PBS, and blocked with 1% BSA-PBS. Cells were incubated with rabbit anti-JEV serum in 2% BSA-PBS at room temperature for 30 min, followed by incubation with HRP-conjugated anti-rabbit IgG antibody (Nichirei, Tokyo, Japan). Infectious foci were detected with 3,3'-diaminobenzidine (DAB; Nichirei).
Enzyme-linked immunosorbent assay (ELISA). ELISA was performed as described by Flow cytometry. Cells were resuspended with cell-dissociation buffer (Invitrogen, Carlsbad, CA) and washed twice with PBS. Virus and soluble CS mixtures were incubated at 4 °C for 30 min, added to dissociated cells, and incubated at 4 °C for 1 h. Cells were washed twice with PBS and fixed with 1% paraformaldehyde-PBS for 10 min. After washing 3 times with PBS, the cells were stained for 30 min with rabbit anti-JEV serum and incubated with Alexa-488-conjugated anti-rabbit IgG (Invitrogen). All labeling steps were performed on ice.
Cells were analyzed with a FACS Canto system (BD Biosciences, San Diego, CA). 
Real

Results
sCS-E inhibits JEV infection of Vero and BHK cells. Many researchers have used
soluble GAGs to study the interaction between GAGs and viruses [5] [6] [7] 12] . To determine which types of CS preparations can influence JEV infection, we incubated the virus with various types of soluble CS preparations at 4 °C for 30 min and then inoculated Vero cells with each mixture. After 48 h, infected cells were detected by using an indirect immunofluorescence assay for JEV antigen. Among the soluble CS preparations examined, only sCS-E effectively inhibited JEV infection (Fig. 1A) . This inhibitory effect of sCS-E was also observed in the JEV infection of BHK cells (Fig. 1B) . The focus reduction assay on BHK cells revealed that the level of this inhibition was dependent on the concentration of sCS-E (Fig. 1C ). [3-7, 13, 14] . We examined whether JEV directly interacts with sCS-E. An ELISA experiment showed that JEV significantly bound to wells precoated with sCS-E but not those bound with other soluble CS (Fig. 1D ). To confirm whether sCS-E inhibited the binding of JEV to cells, a flow cytometric analysis was performed in which virus bound on the Vero cell surface at 4 °C was detected with anti-JEV serum. Preincubation of the virus with sCS-E reduced the amount of bound virus compared to mock preincubation or preincubation with other soluble CS (Fig. 1E ).
sCS-E inhibits JEV binding to Vero and BHK cells. Previous studies on the relationship between GAGs and viral infection have suggested that soluble GAGs inhibit various viral infections by blocking viral entry
sCS-E enhances JEV infection of Neuro-2a cells. Because the neuron is a major target cell in JEV infection, we investigated the effect of soluble CS treatment on the neuroblastoma cell line Neuro-2a under the same condition as was used in nonneural Vero and BHK cells.
Among the soluble CS preparations examined, only sCS-E increased JEV infection ( Fig.   2A-B) , and it did so in a manner that was dependent on the sCS-E concentration (Fig. 2C) .
sCS-E enhances JEV replication in Neuro-2a cells. Because sCS-E had different effects
on Neuro-2a cells from those on Vero or BHK cells, we investigated the influence of sCS-E on the binding of JEV to Neuro-2a cells. Flow cytometric analysis revealed that sCS-E inhibited the attachment of JEV to the Neuro-2a cell surface (Fig. 2D) , as was also observed in Vero cells (Fig. 1E) . To examine the effect of sCS-E treatment on the post-attachment stage, we next investigated the possible increase of viral RNA in infected cells. As shown in Fig. 2E and F, enhancement of viral RNA replication by sCS-E treatment was observed in Neuro-2a cells, but not in Vero cells. These results suggest that the sCS-E-induced enhancement of viral infection in Neuro-2a cells was attributable to enhanced viral replication rather than to increased viral attachment to the cells.
sCS-E enhances JEV infection in vivo. We next examined the effect of sCS-E on JEV
infection in rat brains. Rats over 17 days old reportedly are resistant to intracerebrally administered JEV [15] . In this study, intracerebral co-inoculation of sCS-E together with JEV in 17-day-old rats resulted in a 100-fold increase in brain viral load compared to rats inoculated with JEV alone (Fig. 3A) . Immunohistochemically, more JEV-positive neurons were observed in sCS-E-treated rats than rats not treated with sCS-E ( Fig. 3B and C) .
JEV-positive cells were found in the cerebral cortex, caudate putamen, and hippocampus, and were present focally in the subventricular region, and the positive signal was almost observed in the cytoplasm of neurons (see Fig 3C, inset) . A number of viruses reportedly utilize cell surface PGs as receptors, including human immunodeficiency virus [6] , herpes simplex virus (HSV) [3, 5, 7] , and cytomegalovirus (CMV) [4] . Soluble forms of GAGs are known to inhibit the entry process of these viruses.
Discussion
For example, soluble heparan sulfate inhibits the HSV infection of Vero, HepG-2, CHO, and mouse L cells [13] , and it also inhibits the CMV infection of human foreskin fibroblasts and human embryonic lung fibroblasts [14] . Flaviviruses, such as JEV, yellow fever virus, West Nile virus, Murray Valley encephalitis (MVE), and St. Louis encephalitis virus, have variable affinities for GAGs; this property contributes to viral attachment to host cells [8, 12, [16] [17] [18] [19] [20] [21] .
The high affinity of an attenuated JEV strain for heparan sulfate is known to be responsible for its reduced virulence after peripheral inoculation, due to the rapid clearance of the virus from the bloodstream by the reticuloendothelial system [8] . A previous study on the antiviral activity of sCS-E on DENV infection demonstrated that sCS-E inhibits JEV infection in BHK cells and mentioned the possibility of its use as an antiviral drug [22] .
In our study, sCS-E inhibited JEV entry at an early stage of infection. However, the potential use of sCS-E as an antiviral agent against JEV infection should be approached with caution because, although sCS-E inhibited JEV infection in nonneural cells (e.g., Vero and BHK cells), it enhanced viral replication in a neural cell line and in brain, the main targets of JEV. Studies on the relationship between GAGs and virus infection may need to include a study of the effects of GAGs in natural target cells and organs.
The precise mechanism for the enhancement of viral replication remains uncertain. One possibility is that this enhancement effect involves the suppression of the innate immune response, which is a major host defense mechanism against viral infection in neural cells. In fact, we found that the high-level of constitutive IFN-α expression observed in Neuro-2a cells was inhibited by sCS-E treatment (data not shown).
In conclusion, our data show that sCS-E has paradoxical effects on JEV infection depending on the cell type. A trial use of sCS-E as an antiviral drug against JEV infection may require special attention be given to its effects in the neuron, the major target of JEV. 
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